You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 18, 2024

Details for Patent: 6,229,002


✉ Email this page to a colleague

« Back to Dashboard


Title: Platelet derived growth factor (PDGF) nucleic acid ligand complexes
Abstract:This invention discloses a method for preparing a complex comprised of a PDGF Nucleic Acid Ligand and a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound by identifying a PDGF Nucleic Acid Ligand by SELEX methodology and associating the PDGF Nucleic Acid Ligand with a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound. The invention further discloses Complexes comprising one or more PDGF Nucleic Acid Ligands in association with a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound. The invention further includes a Lipid construct comprising a PDGF Nucleic Acid Ligand or Complex and methods for making the same.
Inventor(s): Janjic; Nebojsa (Boulder, CO), Gold; Larry (Boulder, CO)
Assignee: NeXstar Pharmaceuticlas, Inc. (Boulder, CO)
Filing Date:Dec 16, 1997
Application Number:08/991,743
Claims:1. A Complex comprised of a platelet-derived growth factor (PDGF) Nucleic Acid Ligand and a Non-Immunogenic, High Molecular Weight Compound.

2. The Complex of claim 1 further comprising a Linker between said Ligand and said Non-Immunogenic, High Molecular Weight Compound.

3. The Complex of claim 1 wherein said Ligand comprises a Linker.

4. The Complex of claim 1 wherein said Non-Immunogenic, High Molecular Weight Compound is a Polyalkylene Glycol.

5. The Complex of claim 4 wherein said Polyalkylene Glycol is polyethylene glycol.

6. The Complex of claim 5 wherein said polyethylene glycol has a molecular weight of about 10-80 K.

7. The Complex of claim 6 wherein said polyethylene glycol has a molecular weight of about 20-45 K.

8. A Lipid Construct comprising the Complex of claim 1.

9. The Complex of claim 1 wherein said PDGF Nucleic Acid Ligand is identified from a Candidate Mixture of Nucleic Acids according to the method comprising:

a) contacting the Candidate Mixture with PDGF, wherein the Nucleic Acids having an increased affinity to PDGF relative to the Candidate Mixture may be partitioned from the remainder of the Candidate Mixture;

b) partitioning the increased affinity Nucleic Acids from the remainder of the Candidate Mixture; and

c) amplifying the increased affinity Nucleic Acids to yield a mixture of Nucleic Acids enriched for Nucleic Acids having an increased affinity for PDGF; whereby a Nucleic Acid Ligand of PDGF is identified.

10. The Complex of claim 9 wherein the method further comprises repeating steps b) and c).

11. The complex of claim 7 wherein said Complex is ##STR36##

in which said PEG spacer is ##STR37##

and said nucleic acid ligand comprises SEQ ID NO:146.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.